A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis

NCT06619522 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped 0 participant accrual

Conditions

Myelofibrosis

Interventions

DRUG: Ruxolitinib
DRUG: INCB57643

Sponsor

M.D. Anderson Cancer Center